- Home
- Equipment
- north america
- oncology product
Refine by
Oncology Product Equipment Supplied In North America
7 equipment items found
Manufactured by:Eupraxia Pharmaceuticals based inVictoria, BRITISH COLUMBIA (CANADA)
Eupraxia hopes to add 1-2 additional candidates to our pipeline within the next year, including an internally developed oncology product. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
CB-1158 dihydrochloride (INCB01158 dihydrochloride) is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM forrecombinant human arginase 1 andrecombinant human arginase 2, respectively. Immuno-oncology ...
Manufactured by:MiraDx based inLos Angeles, CALIFORNIA (USA)
Radiation therapy is a form of cancer treatment that is used in over 2/3 of cancer patients diagnosed every year. Although generally, radiation is a safe treatment, 5-10% of patients will experience serious side effects from treatment. In addition, some patients respond not only locally to radiation, but also have an immune response that can help them to fight their cancer. Miradx is at the ...
Manufactured by:The Suremark Company based inMesa, ARIZONA (USA)
RadTat Cross Hair Markers (100 cross hair markers per ...
Manufactured by:QXMedical based inMontreal, QUEBEC (CANADA)
Biodegradable QXMédical Xpheres Microspheres are the next-generation embolics designed to address the evolving needs in the field of embolization therapy, interventional radiology and interventional radiology ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Uveal melanoma, commonly known as ocular or choroidal melanoma, is a rare cancer of the eye with approximately 2,000 patients diagnosed annually in the U.S. At the time of initial diagnosis, approximately 97% of patients are free of metastasis. However, within five years, approximately 30% of patients will develop metastasis – rising to nearly 50% in the following ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology ...